Corium International (CORI) Earning Favorable News Coverage, Analysis Finds

Media coverage about Corium International (NASDAQ:CORI) has trended positive this week, according to Alpha One Sentiment. Alpha One, a unit of Accern, rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corium International earned a media sentiment score of 0.34 on Alpha One’s scale. Alpha One also assigned news articles about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

A number of brokerages recently commented on CORI. Zacks Investment Research upgraded Corium International from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a research note on Tuesday, June 6th. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $12.00 price objective (up from $10.00) on shares of Corium International in a research note on Friday, May 12th. Jefferies Group LLC set a $8.00 price objective on Corium International and gave the stock a “buy” rating in a research note on Thursday, April 20th. Finally, FBR & Co reissued an “outperform” rating and issued a $13.00 price target (up previously from $12.00) on shares of Corium International in a research note on Tuesday, April 18th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $11.25.

Shares of Corium International (NASDAQ CORI) traded down 2.744% on Tuesday, reaching $7.265. The company had a trading volume of 94,139 shares. The company has a 50-day moving average price of $6.35 and a 200-day moving average price of $4.64. Corium International has a one year low of $2.67 and a one year high of $8.33. The firm’s market cap is $212.37 million.

Corium International (NASDAQ:CORI) last released its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. The firm had revenue of $7.35 million during the quarter, compared to analyst estimates of $6.05 million. Corium International had a negative net margin of 116.59% and a negative return on equity of 1,550.00%. On average, analysts expect that Corium International will post ($1.69) earnings per share for the current fiscal year.

In other news, major shareholder Perceptive Advisors Llc bought 1,902,400 shares of the stock in a transaction dated Thursday, May 25th. The stock was bought at an average cost of $6.25 per share, with a total value of $11,890,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 45.70% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Corium International (CORI) Earning Favorable News Coverage, Analysis Finds” was first published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thestockobserver.com/2017/06/20/corium-international-cori-earning-favorable-news-coverage-analysis-finds.html.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply